Prospective evaluation of XRCC‐1 Arg194Trp polymorphism as bio‐predictor for clinical outcome in locally advanced laryngeal cancer undergoing cisplatin‐based chemoradiation

Background To determine X‐ray repair cross‐complementing 1 gene (XRCC‐1) Arg194Trp polymorphism as bio‐predictor for clinical outcome in advanced laryngeal squamous cell carcinoma undergoing cisplatin‐based chemoradiation (CRT). Methods A total of 150 patients were enrolled in this prospective study. XRCC‐1 Arg194Trp genotyping categorized patients as wild (C/C) and polymorphic (C/T or T/T). The primary endpoint was to assess acute radiation‐induced toxicity (ARIT). Results A significant correlation of skin (P‐ .04) and oral mucosal ARIT (P‐ .01) was noticed in the XRCC‐1 polymorphic variant. A higher treatment response was noted in the polymorphic variant, and it shows a trend toward significance (P‐ .08). With 33 months of median follow‐up, 2‐year progression‐free survival (PFS) and overall survival (OS) of wild vs polymorphic variant were 34.6% vs 46.9% (P‐ .066) and 50.6% vs 62.2% (P‐ .12). Conclusion XRCC‐1 polymorphic variants have significantly higher grade of >2 ARIT and may have improved trend for treatment response and PFS.